drugset / Trial / NCT05167994
Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01）
Phase 2
Recruiting
30 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing Jishuitan Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To investigate the safety and efficacy of preoperative IMRT and concurrent Anlotinib Hydrochloride for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Anlotinib Hydrochloride and Penpulimab for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |